Drug-Drug Intercations and Direct Acting Antiviral Agents Against HCV
A legfontosabb adatok
- Ki végzi
- University of Seville
- Hol
- Spanyolország4 helyszín, 1 országbanVálassz országot a helyszínekhez
- Azonosító
- Állapot
- Toboroz
- Résztvevők
- 728 fő, tervezett
- Kezdés
- 2025. ápr. 30.
- Tervezett befejezés
- 2026. márc.
- A vizsgálat típusa
- Megfigyeléses, 2 csoport
- A regiszteradat frissítve
- 2025. április 15.
Ki vehet részt
MI-összefoglaló
A vizsgálat saját részvételi feltételeiből. Gép olvasta ki az oldalon álló regiszterszövegből, ezért tévedhet. Hogy ki vehet részt, azt a lenti regiszterszöveg és a vizsgálat csapata dönti el.
The trial is looking for people with hepatitis C who were treated with GLE/PIB or SOF/VEL between April 1st, 2018, and July 1st, 2023. They must also have taken at least 1 other medicine or recreational drug.
- Nem
- All sexes can join.
- A betegség stádiuma
- Chronic hepatitis C virus (HCV) infection. People with HCV only and people with both HIV and HCV can join.
- Korábbi kezelés
- People must not have had hepatitis C treatment before. They must have received GLE/PIB or SOF/VEL between April 1st, 2018, and July 1st, 2023.
A részvétel fő kizáró okai
- People who had hepatitis C treatment before cannot join.
- People who took no other medicines or recreational drugs cannot join.
- People who were cared for in private health care cannot join.
- People whose hospital did not have electronic records of all visits and prescribed medicines in their Spanish region cannot join.
A regiszter feltételei, szó szerint
Mind a 6 feltétel megnézéseKevesebb
Ki vehet részt
- Treatment naive patients who received therapy with GLE/PIB or SOF/VEL between April 1st, 2018, and July 1st, 2023, receiving ≥ 1 comedication or recreational drug
- Attended in a hospital with electronic clinical records allowing access to all clinical visits and prescribed medications, both in all hospitals and in primary care institutions of the corresponding Spanish region during the study period
Ki nem vehet részt
- Patients without any comedication or recreational drug use
- HCV treatment-experienced patients will be excluded
- Patients who meet any of the following criteria will be excluded from the study:
- Those who have attended private health care
Ez a vizsgálat jelenleg itt érhető el: Spanyolország.
Egy országban van helyszíne. Válassz országot, hogy lásd a helyszíneket.
A vizsgálatról
Mit akar kideríteni a vizsgálat
Background: Currently used direct-acting antivirals (DAA) share pharmacokinetic pathways with many comedications commonly used in patients with chronic hepatitis C virus (HCV) infection, therefore drug-drug interactions (DDI) might exist. Although extensive (DDI) verification is recommended by most clinical practice guidelines, real-world studies have shown that approximately one-tenth of patients on DAA therapy also take concomitant medication with the potential for significant interactions. Despite the risk of significant DDI when patients are administered DAA and a concomitant medication, to date, there is very little information on whether these interactions translate into changes in the toxicity or efficacy of any involved DAA or comedication in clinical practice. Clarifying this issue is a critical point, as the DDI profile of the currently used DAA is not the same, with SOF/VEL showing a lower risk of significant DDI than GLE/PIB. Thus the objective of this study is to compare the percentage of comedication switch, withdrawal, or dose reduction at treatment initiation and during treatment with GLE/PIB or SOF/VEL.
A teljes eredeti leírásKevesebb
Methods: The patients will be enrolled from the GEHEP 001/HEPAVIR cohort. "The HEPAVIR-DAA cohort (NCT02057003)", includes HIV/HCV-coinfected patients, and "the GEHEP-MONO cohort (NCT02333292)", that includes HCV mono-infected individuals, are ongoing prospective multicenter cohorts of patients receiving DAA combinations prescribed in clinical practice, outside clinical trials. Main Study End Point will be the frequency of comedication switch, withdrawal or dose reduction at treatment initiation (index date) and during treatment with GLE/PIB or SOF/VEL.
A vizsgálat 2 csoportja
- SOF/VEL
Treatment with SOF/VEL (n=485)
- GLE/PIB
Treatment with GLE/PIB (n=243)
Kérdések a vizsgálat csapatának
- Milyen gyakran kell bejárnom, és egy-egy alkalom mennyi ideig tart?
- Megtérítik az utazási költséget?
- Megtarthatom a saját orvosomat?
- Mi történik, ha ki akarok lépni?
Contact the study team: see the registry record → Contacts and Locations
Oldal nyomtatása az orvosomnakAdatok és források
- Regiszteradat
- Szerepel a ClinicalTrials.gov-on.
- Hivatalos cím
- Clinical Relevance of Drug-drug Interactions (DDI) With the Currently Used Direct-acting Antiviral Therapy (DAA) Against Hepatitis C Virus (HCV)
- MI-összefoglaló
- A vizsgálat saját részvételi feltételeiből. Gépi kiolvasás: 2026. november 14.
- A regiszteradat frissítve
- 2025. április 15.